89bio, Inc. Stock: price and insider trades · United States

Competitive positioning in this space is challenging. 89bio operates in a crowded and highly competitive liver/metabolic disease landscape that includes large pharmaceutical companies and well-financed biotech peers pursuing adjacent or overlapping indications. Rather than building a broad commercial portfolio, 89bio has pursued a focused, single-asset strategy designed to maximize the value of pegozafermin. That strategy offers substantial upside if data are positive, but it also creates pronounced binary risk tied to late-stage clinical outcomes, regulatory decisions, and partnering or commercialization outcomes. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1785173/000095017025029243/etnb-20241231.htm))

The most important recent corporate development was the September 18, 2025 announcement that Roche agreed to acquire 89bio. Under the announced terms, 89bio stockholders were to receive $14.50 per share in cash at closing, plus a non-tradeable CVR worth up to an additional $6.00 per share in cash, implying total potential equity value of about $3.5 billion. 89bio stated that it would continue to operate as a separate and independent company until the transaction closes. ([ir.89bio.com](https://ir.89bio.com/news-releases/news-release-details/89bio-inc-announces-agreement-be-acquired-roche/))

For French-speaking investors in France, Belgium, and Switzerland, ETNB is therefore best understood as a clinical biotech with a concentrated pipeline, significant upside tied to one lead asset, and a near-term strategic overlay from the Roche acquisition process. The key variables are no longer only the long-term clinical potential of pegozafermin, but also the completion of the transaction and any remaining milestones that may affect value realization. ([ir.89bio.com](https://ir.89bio.com/news-releases/news-release-details/89bio-inc-announces-agreement-be-acquired-roche/))